Life Sciences

  • March 12, 2026

    Tom's Toothpaste Trims Class Action Over Lead Levels

    Tom's of Maine can't beat back proposed class claims it allowed heavy metals to taint its children's toothpaste, a New York federal judge ruled Wednesday, finding that the parent behind the suit adequately claimed the company falsely marketed the products as "safe" and "healthy."

  • March 12, 2026

    IP Notebook: TM Use Fight, Popeye, Kurt Cobain

    This edition of emerging copyright and trademark cases and trends looks at an appeal before the U.S. Supreme Court that questions the definition of trademark "use in commerce" under the Lanham Act and a battle over the use of "Popeye" as a trademark.

  • March 12, 2026

    Embryo Loss Suits Need 'Serious' Edits, Judge Told

    Two complaints against fertility products maker CooperSurgical Inc. require "serious" amendments to clarify the nature of the claims that a defective culture medium caused embryo losses for in vitro fertilization patients, the company told a Connecticut federal judge Thursday.

  • March 12, 2026

    US Chamber Report Warns Of Risks To IP Protection

    While the U.S. has ranked at the top of the U.S. Chamber of Commerce's list measuring how countries worldwide are enforcing intellectual property laws, the group said problems with free trade agreements and efforts to reduce pharmaceutical prices could cause problems on the horizon domestically.

  • March 12, 2026

    Epilepsy Drugmaker's Statements Insulated From Stock Suit

    A Pennsylvania federal judge has trimmed a shareholder class action against Marinus Pharmaceuticals alleging it misled investors about the probability of success of an epilepsy drug, ruling that certain statements made by company leadership were immunized by the Private Securities Litigation Reform Act.

  • March 12, 2026

    Del. Chancery Rejects Fraud Claims In $313.5M Fertilizer Deal

    The Delaware Chancery Court has ruled that a group of investors failed to prove that executives and a private equity sponsor behind agricultural technology company Verdesian Life Sciences LLC defrauded them into investing in a 2014 acquisition, holding after trial that the claims were both time-barred and unsupported.

  • March 11, 2026

    DNA Testing Co. Can't Shake Suit Over Genetic Data Sharing

    A Massachusetts federal judge refused to release Nebula Genomics Inc. from a proposed class action accusing it of illegally sharing its customers' genetic information with Meta and other third parties through online tracking tools, finding that the parties' choice-of-law agreement didn't extend to the plaintiff's genetic privacy allegation. 

  • March 11, 2026

    Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud

    An Illinois federal judge ordered Eli Lilly and Co. on Tuesday to arbitrate a dispute over millions of dollars in milestone payments allegedly owed under a collaboration agreement to develop an Alzheimer's disease drug, ruling that the drugmaker lacked standing to challenge an underlying security agreement.

  • March 11, 2026

    New Wyoming Abortion Law Faces Familiar Legal Challenge

    Just a day after it was signed into law, Wyoming's new anti-abortion law triggered a legal challenge from the same health clinic that successfully sued over the state's previous abortion limits.

  • March 11, 2026

    La. Fights Dismissal Bid In Abortion Regulation Dispute

    The state of Louisiana urged a federal court to deny motions by GenBioPro Inc. and Danco Laboratories seeking dismissal of its suit challenging federal regulation on mail-order abortion drugs, arguing it has established harms stemming from the regulations.

  • March 11, 2026

    Insulin Makers Ask Justices To Review Collusion Case

    Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP have told the U.S. Supreme Court that a ruling reviving a case over insulin drug costs undermines key rules meant to weed out improper antitrust claims.

  • March 11, 2026

    Pharma Co. Says Ex-Director Using Trade Secrets At New Job

    A specialty infusion therapy pharmacy has accused a former director of contracts of taking valuable trade secrets with her on her way out to work for a rival company.

  • March 11, 2026

    Bayer Sees 'Light At The End Of The Tunnel' In Roundup Suits

    After more than a decade and tens of thousands of cases, a recent settlement announcement and a high-stakes high court hearing may finally give the makers of the weedkiller Roundup an off-ramp in seemingly never-ending litigation.

  • March 11, 2026

    Pa. Justices Doubtful Law Unclear In AG-DA Opioid Deal Row

    Multiple Pennsylvania Supreme Court justices on Wednesday doubted a state law was ambiguous about whether the attorney general could step in and settle claims brought by county-level district attorneys, as he had in a multistate settlement with opioid companies.

  • March 11, 2026

    Anthem Beats Lab's $1.9M ERISA Payment Demand

    Anthem Blue Cross Blue Shield of Connecticut has prevailed in a medical laboratory's $1.9 million contract and ERISA lawsuit over allegations the insurer refused to pay for out-of-network tests.

  • March 11, 2026

    Minn. Lawmakers Advance Medical Psilocybin Bill

    Minnesota lawmakers this week advanced a bipartisan bill to create a regulated medical program for psilocybin, the active ingredient in psychoactive mushrooms.

  • March 11, 2026

    MoFo Private Equity Atty Joins Greenberg Traurig In Miami

    Greenberg Traurig LLP announced Wednesday that a Miami-based private equity attorney has joined the firm's corporate practice from Morrison Foerster LLP.

  • March 11, 2026

    Biomedical Co. Settles Trade Secrets Case Against Ex-Worker

    Biomedical company Skye Orthobiologics and a former employee have informed a California federal judge that they have settled a case accusing the ex-employee of breaching fiduciary duties by leveraging Skye's proprietary information.

  • March 11, 2026

    Investor Urges Revival Of Armistice Insider Trading Claims

    The Delaware Supreme Court has heard arguments over whether a hedge fund that traded tens of millions of dollars' worth of stock can face insider trading liability under state law after its board designee allegedly received confidential company information, with an Aytu BioPharma shareholder urging the court to revive claims against healthcare investor Armistice Capital.

  • March 10, 2026

    Justices Advised To Keep Law Clear In 'Skinny Label' Case

    Several intellectual property groups have urged the U.S. Supreme Court to use a case involving "skinny labels" on generic drugs to set clear guidelines on what constitutes induced patent infringement, saying the outcome has implications beyond pharmaceuticals.

  • March 10, 2026

    J&J Unit Wins Sanction In Talc Libel Case

    A Virginia federal judge on Tuesday issued sanctions against a doctor being sued by a Johnson & Johnson unit over an article linking mesothelioma with talc products, saying that a jury will be told that he deleted emails about the article when he was legally obligated to keep them.

  • March 10, 2026

    5th Circ. Revives J&J Sales Rep's Wage Dispute

    A Texas federal court did not take into consideration relevant factors to determine whether a former Johnson & Johnson sales representative's failure to retain local counsel in his wage and hour suit represented excusable neglect, the Fifth Circuit ruled on Tuesday.

  • March 10, 2026

    Sanofi Says Judge Botched Insulin Device Patent Listings

    Sanofi-Aventis sparred with drug wholesalers over a Massachusetts federal magistrate judge's pronouncements that the parties should go to trial on claims the pharmaceutical giant used improper insulin device patent listings to anticompetitively protect the blockbuster Lantus insulin pen from competition.

  • March 10, 2026

    Lab's Aetna Payment Suit Survives, But With Deep Cuts

    A Connecticut federal judge ruled Aetna and its parent company, CVS Health Corp., must face a pared down lawsuit from a medical laboratory alleging it is owed $20.6 million in unpaid invoices.

  • March 10, 2026

    FDA To Consider Coffee, 'Spice' E-Cig Flavors

    The U.S. Food and Drug Administration on Monday indicated that it would be willing to consider e-cigarette flavors shown to be less attractive to youth, like coffee or spices, a move that's come under fire from public health advocates.

Expert Analysis

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

  • Trends In Post-Grant Practice Since USPTO Denial Guidance

    Author Photo

    Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.